secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001447028-23-000052
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus shareholders approve 3.5M share increase to 2016 equity incentive plan
------------------------------------------------------------------------------

- Shareholders approved amendment to 2016 Omnibus Plan, increasing authorized shares by 3,500,000 (85.6M for, 9.0M against).
- All six director nominees elected: Frank Torti, William Collier, Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers.
- Non-binding advisory vote on named executive officer compensation approved (85.6M for, 8.2M against, 1.1M abstain).
- Ratification of Ernst & Young as independent auditor for 2023 approved (125.7M for, 0.8M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000144702823000052/0001447028-23-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000144702823000052/abus-20230524.htm
  HTML page:      https://secwatch.observer/filing/0001447028-23-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer